SciSparc (SPRC) EBT Margin (2016 - 2022)
SciSparc (SPRC) posted EBT Margin of 30.74% for Q4 2022, up 37.22% sequentially from 48.96% in Q3 2022.
SciSparc (SPRC) EBT Margin (2016 - 2022) Analysis & Trends
SciSparc has reported EBT Margin for 4 years, with the latest figure at 30.74% in Q4 2022.
- Quarterly EBT Margin changed N/A year-over-year to 30.74% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 587.25% (changed N/A YoY) and the FY2025 annual result came in at 1467.76%, down 89456.0% from the prior year.
- EBT Margin advanced to 30.74% in Q4 2022 per SPRC's latest filing, from 48.96% in the prior quarter.
- Over five years, EBT Margin peaked at 66.2% in Q3 2018 and troughed at 358.86% in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 12.09% |
| 10 | SciSparc | 807,202.50 | 807,202.50 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -30.74% |
| Sep 30, 2022 | -48.96% |
| Dec 31, 2018 | -358.86% |
| Sep 30, 2018 | 66.20% |
| Jun 30, 2018 | -89.70% |
| Mar 31, 2018 | 3.94% |
| Dec 31, 2017 | -267.39% |
| Sep 30, 2017 | -10.42% |
| Jun 30, 2017 | -121.95% |
| Mar 31, 2017 | -48.84% |
| Sep 30, 2016 | -3.17% |
| Jun 30, 2016 | -3.31% |